Neurotrope Shareholders to Own 49 Percent of Petros Under Revised Merger Agreement with Metuchen
Neurotrope Shareholders, Currently Representing 34 Percent of Shares Outstanding, Sign Agreement in Support of Merger
Petros to Grow Stendra® and Explore Non-Prescription / Over-the-Counter Strategies for Stendra® in Partnership with Foundation Consumer Healthcare, a Juggernaut Capital portfolio investment and One of the Largest Pure-Play OTC Companies in the U.S.
Company to be Led by Fady Boctor as President and Chief Commercial Officer. John Shulman, Founder and Managing Partner of Juggernaut Capital Partners, will become Executive Chairman of the Board
NEW YORK and MANALAPAN TOWNSHIP, N.J., Sept. 30, 2020 /PRNewswire/ — Neurotrope, Inc. (Nasdaq: NTRP) and Metuchen Pharmaceuticals, L.L.C., a privately held biopharmaceutical company focused on innovative therapeutics for men’s health conditions (“Metuchen”), today announced that they have entered into an amendment to their definitive merger agreement (“Amended Merger Agreement”) under which the consideration due to Neurotrope stockholders will increase to 49% of the combined company on a pro forma basis and based upon the final Neurotrope common stock share count at close (Under terms of the Merger Agreement dated July 23, 2020, Neurotrope stockholders were to own approximately 22.5% of the combined company.) Neurotrope and Metuchen previously announced their intent to merge in an all-stock transaction resulting to form a NASDAQ-traded holding company to be named Petros Pharmaceuticals, Inc. (“Petros”). As part of the Amended Merger Agreement, Neurotrope shareholders currently representing 34% of the Company’s outstanding shares have signed a shareholder rights agreement in support of the merger.
Consistent with the original Merger Agreement, under terms of the Amended Merger Agreement, upon closing of the transaction, Neurotrope Bioscience Inc.’s (“NBI”) current lead asset, Bryostatin-1 to treat neurodegeneration, and substantially all of its existing assets, operations and liabilities, except for cash retained by Petros in accordance with the terms of the Amended Merger Agreement, will be spun-out into a new, separately traded company. The Amended Merger Agreement has been approved by the boards of directors of both companies.
“With this amendment, Neurotrope investors are being offered nearly half ownership in Petros while retaining full interest in NBI, with both companies expected to be publicly traded,” said Mr. Silverman. “We believe this provides a far more compelling stake in two distinct opportunities, one continuing the exciting clinical development of Bryostatin-1 in an NIH-supported study in Alzheimer’s disease, and the other building on a commercial asset in Stendra® with substantial upside potential.”
As part of the strategy of enhancing value to its existing drug portfolio, Petros will be led by a streamlined management team and will focus on its two core assets: Stendra®, a phosphodiesterase-5 (PDE-5) inhibitor and the only oral, patented erectile disfunction (ED) product on the market, as well as H-100, an innovative, non-invasive topical treatment candidate for Peyronie’s disease (PD). Petros will be led by Fady Boctor, Chief Commercial Officer of Metuchen, who will be named President and CCO. Mr. Boctor has extensive industry experience in men’s health, particularly in the areas of ED and PD. A new board of directors will be installed and John Shulman, Founder and Managing Partner of Juggernaut Capital Partners (“JCP”), a leading private equity firm with over $1 billion in capital commitments, will become Executive Chairman of the Board. In line with Petros’ more focused strategy, Charles S. Ryan, J.D., Ph.D., Neurotrope’s Chief Executive Officer, will transition to a senior consulting role to Petros.
Petros will explore the potential to convert Stendra® from prescription-only status to non-prescription status. Stendra® is a distinct oral prescription therapeutic that may be taken as early as approximately 15 minutes prior to intimate engagement, with or without food, and has a clinically proven safety profile, including a discontinuation rate due to adverse events comparable to placebo. Petros will partner with Foundation Consumer Healthcare (“FCH”) in this effort. FCH is a long-time portfolio investment of JCP and is one of the largest pure-play Over-the-Counter (“OTC”) companies in the U.S. FCH is dedicated to improving consumers’ lives by developing and growing a portfolio of differentiated OTC products, including the single highest selling SKU in the OTC category: Plan B One Step®. The company is led by President and CEO Greg Bradley, who has deep industry experience within the OTC healthcare landscape in senior roles at GlaxoSmithKline Consumer Healthcare (GSK) and other organizations.
“Erectile dysfunction is a condition that affects 30 million men in the U.S., and yet only 25% of men have accessed ED therapies,” said Mr. Boctor. “OTC availability has a long track record of increasing access to well-tolerated and effective medicines. We look forward to exploring this opportunity for Stendra® together with Foundation Consumer Healthcare.”
Neurotrope plans to hold a special meeting of stockholders to approve the pending transaction mid-fourth quarter 2020. The transaction is expected to close shortly thereafter, subject to customary closing conditions, including approval of the amended Merger Agreement by Neurotrope stockholders.
Lead Asset Stendra® (avanafil)
Stendra® (avanafil), originally launched by Auxilium Pharmaceuticals prior to that company’s sale to Endo Pharmaceuticals, is an oral phosphodiesterase 5 (PDE5) inhibitor for the treatment of ED that can be dosed as early as ~15 minutes before sexual activity, can be taken with or without food, and is well tolerated, with a rate of discontinuation (2.0%) comparable to placebo (1.7%) in clinical trials. Stendra® was designed and developed expressly for erectile dysfunction. Metuchen recently undertook a relaunch of Stendra®, following Juggernaut’s acquisition of a majority position in Metuchen in 2018, generating gross revenues of approximately $30 million in 2019. Upon closing of the merger, Petros intends to accelerate the relaunch of Stendra® with a well-funded commercial organization and refocused strategy. Currently, Stendra® is covered for 75% of commercially insured lives, with a co-pay as low as $0.
Lead Pipeline Program H100™
Metuchen’s lead pipeline program includes the recently in-licensed drug candidate H-100, a non-invasive, compounded, topical treatment for Peyronie’s disease (PD). In its current formulation, H-100 demonstrated positive efficacy and tolerability in a 22 patient prospective, randomized, double-blind, placebo-controlled study in patients with PD. Metuchen intends to optimize manufacturing and the patented formulation of H-100, then seek FDA guidance on the studies necessary to achieve approval and labeling of the product. PD is a progressive, wound-healing disorder of the penis involving the formation of plaques and the subsequent development of penile curvature or indentations. The current non-surgical standard of care in PD, an injectable, was granted Orphan Designation by the FDA in 1996.
“As a topical treatment, we believe H-100 can have a transformative effect on the management of a disease that causes pain, anxiety and psychological distress,” said Fady Boctor, Chief Commercial Officer of Metuchen. “Our goal is to deliver on this promise rapidly and cost effectively with a proprietary, clinically validated therapeutic.”
About STENDRA® (avanafil)
STENDRA® (avanafil) is approved in the U.S. by the FDA for the treatment of erectile dysfunction. Metuchen Pharmaceuticals LLC has exclusive marketing rights to STENDRA® in the U.S., Canada, South America and India.
STENDRA® is available through retail and mail order pharmacies.
For more information about STENDRA®, please visit www.STENDRA.com.
Important Safety Information
STENDRA® (avanafil) is prescribed to treat erectile dysfunction (ED).
Do not take STENDRA® if you take nitrates, often prescribed for chest pain, as this may cause a sudden, unsafe drop in blood pressure.
Discuss your general health status with your healthcare provider to ensure that you are healthy enough to engage in sexual activity. If you experience chest pain, nausea, or any other discomforts during sex, seek immediate medical help.
STENDRA® may affect the way other medicines work. Tell your healthcare provider if you take any of the following; medicines called HIV protease inhibitors, such as ritonavir (Norvir®), indinavir (Crixivan®), saquinavir (Fortavase® or Invirase®) or atazanavir (Reyataz®); some types of oral antifungal medicines, such as ketoconazole (Nizoral®), and itraconazole (Sporanox®); or some types of antibiotics, such as clarithromycin (Biaxin®), telithromycin (Ketek®), or erythromycin.
In the rare event of an erection lasting more than 4 hours, seek immediate medical help to avoid long-term injury.
In rare instances, men taking PDE5 inhibitors (oral erectile dysfunction medicines, including STENDRA®) reported a sudden decrease or loss of vision. It is not possible to determine whether these events are related directly to these medicines or to other factors. If you experience sudden decrease or loss of vision, stop taking PDE5 inhibitors, including STENDRA®, and call a doctor right away.
Sudden decrease or loss of hearing has been rarely reported in people taking PDE5 inhibitors, including STENDRA®. It is not possible to determine whether these events are related directly to the PDE5 inhibitors or to other factors. If you experience sudden decrease or loss of hearing, stop taking STENDRA® and contact a doctor right away. If you have prostate problems or high blood pressure for which you take medicines called alpha blockers or other anti-hypertensives, your doctor may start you on a lower dose of STENDRA®.
Drinking too much alcohol when taking STENDRA® may lead to headache, dizziness, and lower blood pressure.
STENDRA® in combination with other treatments for ED is not recommended.
STENDRA® does not protect against sexually transmitted diseases, including HIV.
The most common side effects of STENDRA® are headache, flushing, runny nose and congestion.
Please see full patient prescribing information for STENDRA® (50 mg, 100 mg, 200 mg) tablets.
About Neurotrope Bioscience, Inc.
NBI is a clinical-stage biopharmaceutical company that has historically worked to develop novel therapies for neurodegenerative diseases. NBI has conducted clinical and preclinical studies of its lead therapeutic candidate, Bryostatin-1, in Alzheimer’s disease, and preclinical studies for rare diseases and brain injury, including Fragile X syndrome, multiple sclerosis, stroke, Niemann-Pick Type C disease, Rett syndrome, and traumatic brain injury. The FDA has granted Orphan Drug Designation to NBI for Bryostatin-1 as a treatment for Fragile X syndrome. Bryostatin-1 has already undergone testing in more than 1,500 people in cancer studies, thus creating a large safety data base that will further inform clinical trial designs.
Additional information about Neurotrope may be found on its website: www.neurotrope.com.
About Metuchen Pharmaceuticals
Metuchen pharmaceuticals is committed to becoming the world’s leading men’s health company by identifying, developing, acquiring, and commercializing innovative therapeutics for men’s health issues including, but not limited to erectile dysfunction, endothelial dysfunction, psychosexual and psychosocial ailments, Peyronie’s disease (acute and chronic), hormone health and substance use disorders.
No Offer or Solicitation
This communication shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No public offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.
Important Additional Information Will be Filed with the SEC
In connection with the proposed transaction between Petros, Neurotrope and Metuchen, Petros intends to file relevant materials with the SEC, including a registration statement that will contain a proxy statement and prospectus. BEFORE MAKING ANY VOTING OR INVESTMENT DECISION, INVESTORS AND STOCKHOLDERS ARE URGED TO READ THE PROXY STATEMENT/PROSPECTUS (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS THAT NEUROTROPE MAY FILE WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTIONS. Stockholders may obtain, free of charge, copies of the definitive proxy statement/prospectus and any other documents filed by Petros with the SEC in connection with the proposed transactions at the SEC’s website (www.sec.gov), at Neurotrope’s website: www.neurotrope.com, or by directing written request to: Neurotrope, Inc., 1185 Avenue of the Americas, 3rd Floor, New York, New York 10036, Attention: Robert Weinstein.
Participants in the Solicitation
Petros, Neurotrope, Metuchen and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of Neurotrope in connection with the proposed transaction. Information regarding the special interests of these directors and executive officers in the merger will be included in the proxy statement/prospectus referred to above. Additional information regarding the directors and executive officers of Neurotrope is also included in Neurotrope’s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on March 13, 2020. This document is available free of charge at the SEC web site (www.sec.gov), at Neurotrope’s website, or by directing a written request to Neurotrope as described above.
Cautionary Note Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. These forward-looking statements include statements regarding Petros, Neurotrope, Metuchen, the combined company, the proposed transaction and other matters. Such forward-looking statements are subject to risks and uncertainties and other influences, many of which Neurotrope has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties, including, without limitation: the risk that the conditions to the closing of the proposed transactions are not satisfied, including the failure to obtain stockholder approval for the proposed transactions in a timely manner or at all; uncertainties as to the timing of the consummation of the proposed transactions and the ability of each of Petros, Neurotrope and Metuchen to consummate the proposed transactions; risks related to Petros’ initial listing on The Nasdaq Capital Market at the closing of the proposed transactions; risks related to Neurotrope’s ability to correctly estimate its operating expenses and its expenses associated with the proposed transactions; the ability of Neurotrope or Metuchen to protect their respective intellectual property rights; competitive responses to the transaction; unexpected costs, charges or expenses resulting from the proposed transactions; potential adverse reactions or changes to business relationships resulting from the announcement or completion of the proposed transactions; and legislative, regulatory, political and economic developments; expectations regarding the industry and business operations of Petros. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including Neurotrope’s filings with the Securities and Exchange Commission, including Neurotrope’s Annual Report on Form 10-K for the year ended December 31, 2019, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K filed with the SEC. Neurotrope can give no assurance that the conditions to the proposed transactions will be satisfied. Except as required by applicable law, Neurotrope does not undertake to update these forward-looking statements.
Contact information:
Investors and Media
Lisa Sher
Argot Partners
petros@argotpartners.com
212-600-1902
Juggernaut/Metuchen
Deirdre Walsh
Abernathy MacGregor
dlw@abmac.com
212-371-5999
